ArticleFrontiers in oncology2026
Adaptive dosing of immunotherapy plus anti-angiogenic therapy in a nonagenarian with hepatocellular carcinoma: a case report with 10-year survival.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elderly cancer patients, particularly those aged ≥90 years, are significantly underrepresented in clinical trials, leaving a critical evidence gap for this growing population. Case presentation: We report a 90-year-old man with multiple comorbidities (coronary artery disease, hypertension, type 2 diabetes, hyperlipidaemia, hepatic steatosis, and hypothyroidism) and an ECOG performance status 2, who was diagnosed with hepatocellular carcinoma (HCC) in 2015. After initial microwave ablation in 2017 and for recurrence in 2021, he developed multifocal intrahepatic progression in January 2023 at age 97. Following progression on pembrolizumab monotherapy (100 mg q3w) and intolerance to lenvatinib combination, treatment was adapted to reduced-dose pembrolizumab (100 mg q3w) plus reduced-dose bevacizumab (3.75 mg/kg q3w)-approximately half and one-quarter of standard doses, respectively. He achieved partial response after three cycles with significant symptomatic improvement. As of March 2025 (age 99), he has completed 23 cycles with a progression-free survival of 15 months. He maintains functional independence, satisfactory symptom control (liver pain NRS 1-2), and only grade 1 fatigue, with no treatment-related hospitalizations. Conclusion: To our knowledge, this is the oldest reported patient with HCC to receive combined immunotherapy and anti-angiogenic therapy. This case suggests that with carefully adapted dosing-using approximately half-dose pembrolizumab and quarter-dose bevacizumab-a nonagenarian with multiple comorbidities may achieve prolonged disease control, challenging the conventional 'one-size-fits-all' dosing paradigm and highlighting the feasibility of individualized treatment strategies in the oldest-old population with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.